Bevacizumab (Avastin®) for platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer
Ludwig Boltzmann Institute for Health Technology Assessment
Record ID 32014001411
English
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://eprints.hta.lbg.ac.at/1038/1/DSD_HSO_Nr.48.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Austria
MeSH Terms
- Humans
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols
- Organoplatinum Compounds
- Treatment Outcome
- Ovarian Neoplasms
- Neoplasm Recurrence, Local
- Disease-Free Survival
- Carcinoma, Papillary
- Fallopian Tube Neoplasms
- Peritoneal Neoplasms
- Female
- Neoplasm Staging
Contact
Organisation Name:
Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address:
Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name:
tarquin.mittermayr@aihta.at
Contact Email:
office@aihta.at
Copyright:
Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.